BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Zhang L, Xue S, Hou J, Chen G, Xu ZG. Endothelin receptor antagonists for the treatment of diabetic nephropathy: A meta-analysis and systematic review. World J Diabetes 2020; 11(11): 553-566 [PMID: 33269066 DOI: 10.4239/wjd.v11.i11.553]
URL: https://www.wjgnet.com/2220-3168/full/v11/i11/553.htm
Number Citing Articles
1
Giovanna Capolongo, Giovambattista Capasso, Davide Viggiano. A Shared Nephroprotective Mechanism for Renin-Angiotensin-System Inhibitors, Sodium-Glucose Co-Transporter 2 Inhibitors, and Vasopressin Receptor Antagonists: Immunology Meets HemodynamicsInternational Journal of Molecular Sciences 2022; 23(7): 3915 doi: 10.3390/ijms23073915
2
Antony Sameh Mansour. Autoregulation: mediators and renin–angiotensin system in diseases and treatmentsFuture Journal of Pharmaceutical Sciences 2023; 9(1) doi: 10.1186/s43094-023-00482-4
3
Te-Ling Lu, Sheng-Nan Wu. Investigating the Impact of Selective Modulators on the Renin–Angiotensin–Aldosterone System: Unraveling Their Off-Target Perturbations of Transmembrane Ionic CurrentsInternational Journal of Molecular Sciences 2023; 24(18): 14007 doi: 10.3390/ijms241814007
4
Alessio Mazzieri, Francesca Porcellati, Francesca Timio, Gianpaolo Reboldi. Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of NephroprotectionInternational Journal of Molecular Sciences 2024; 25(7): 3969 doi: 10.3390/ijms25073969
5
Katherine R. Tuttle, Rajiv Agarwal, Charles E. Alpers, George L. Bakris, Frank C. Brosius, Peter Kolkhof, Jaime Uribarri. Molecular mechanisms and therapeutic targets for diabetic kidney diseaseKidney International 2022; 102(2): 248 doi: 10.1016/j.kint.2022.05.012
6
Susan Miller, Walter Moos, Barbara Munk, Stephen Munk, Charles Hart, David Spellmeyer. Managing the Drug Discovery Process2023; : 207 doi: 10.1016/B978-0-12-824304-6.00001-8
7
Noorain Ahmad, Harish Veerapalli, Chetan Reddy Lankala, Everardo E Castaneda, Afia Aziz, Amy G Rockferry, Pousette Hamid. Endothelin Receptor Antagonists as a Potential Treatment of Diabetic Nephropathy: A Systematic Review Cureus 2021;  doi: 10.7759/cureus.19325
8
Tzu-Hsien Chuang, Hsin-Yen Cho, Sheng-Nan Wu. The Evidence for Sparsentan-Mediated Inhibition of INa and IK(erg): Possibly Unlinked to Its Antagonism of Angiotensin II or Endothelin Type a ReceptorBiomedicines 2021; 10(1): 86 doi: 10.3390/biomedicines10010086
9
Yang Yang, Gaosi Xu. Update on Pathogenesis of Glomerular Hyperfiltration in Early Diabetic Kidney DiseaseFrontiers in Endocrinology 2022; 13 doi: 10.3389/fendo.2022.872918
10
Kimio Watanabe, Emiko Sato, Eikan Mishima, Mariko Miyazaki, Tetsuhiro Tanaka. What’s New in the Molecular Mechanisms of Diabetic Kidney Disease: Recent AdvancesInternational Journal of Molecular Sciences 2022; 24(1): 570 doi: 10.3390/ijms24010570
11
Wei Huang, Yi-Yuan Chen, Zi-Qi Li, Fang-Fang He, Chun Zhang. Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney DiseasesInternational Journal of Molecular Sciences 2022; 23(18): 10882 doi: 10.3390/ijms231810882
12
Zeinab H. El-Said, Sherihan I. Gouda, Hebatallah A. Mahgoub, S El_desouky, Neven A. Ebrahim. L- Thyroxine ameliorates renal function in thyroidectomized diabetic nephropathy rats through downregulation of TGF- β1, Ang II and ET-1 expressionEgyptian Journal of Basic and Applied Sciences 2023; 10(1): 632 doi: 10.1080/2314808X.2023.2248711